Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction

AIMS: Despite well‐established benefits of sacubitril/valsartan for cardiac reverse remodelling and the prognosis of patients with heart failure with reduced ejection fraction (HFrEF), there are some patients with limited therapeutic response, even with optimal therapy. We assessed the treatment res...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:ESC Heart Fail
Hlavní autoři: Moon, Mi‐Gil, Hwang, In‐Chang, Choi, Wonsuk, Cho, Goo‐Yeong, Yoon, Yeonyee E., Park, Jun‐Bean, Lee, Seung‐Pyo, Kim, Hyung‐Kwan, Kim, Yong‐Jin
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2021
Témata:
Original Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8120366/
https://ncbi.nlm.nih.gov/pubmed/33682334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.13285
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky